Palvella Therapeutics

Palvella Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious, rare genetic skin diseases. Founded in 2015, the company is driven by the mission to provide treatment options for individuals suffering from these often debilitating and visible conditions. Their primary focus lies in developing targeted topical treatments using their patented QTORIN™ platform. This platform aims to overcome challenges associated with topical drug delivery, such as achieving therapeutic concentrations and minimizing systemic absorption.

Palvella's initial product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in late-stage clinical development for various rare skin diseases like Microcystic Lymphatic Malformations (Micro LM), Basal Cell Carcinomas (BCCs) in Gorlin Syndrome (GS), and Pachyonychia Congenita (PC). The company has garnered significant recognition for its efforts, including Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for several of its programs. This ongoing research and development indicate Palvella's commitment to transforming the treatment landscape for individuals living with rare genetic skin diseases.

Palvella Therapeutics is a clinical-stage biopharmaceutical company dedicated to serving individuals suffering from rare genetic skin diseases by developing and commercializing novel therapies for which there are no FDA-approved treatments. Driven by a commitment to patient advocacy and a robust understanding of disease pathology, Palvella leverages its patented QTORIN™ platform to create targeted topical treatments that address the unmet needs of those living with debilitating, lifelong skin conditions.

Palvella Therapeutics cultivates a collaborative and passionate culture, driven by a strong commitment to serving individuals affected by rare genetic skin diseases. Their team is comprised of highly credentialed professionals who work together to advance transformative treatments. The company prioritizes patient advocacy and building meaningful partnerships with disease advocacy organizations, recognizing the importance of understanding the lived experiences of those impacted by these conditions. This dedication to making a difference in the lives of patients permeates their work and fosters a sense of purpose among their employees.

Palvella Therapeutics is committed to building a diverse, equitable, and inclusive workplace. They believe that a diverse team fosters creativity and innovation, leading to better scientific discoveries and treatments. The company actively seeks out and supports diverse candidates, creates a welcoming and inclusive environment for all employees, and collaborates with patient advocacy organizations to better understand the diverse needs of their target communities.